UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 or 15(d) of the

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): August 30, 2023

MOONLAKE IMMUNOTHERAPEUTICS

(Exact Name of Registrant as Specified in Its Charter)

Dorfstrasse 29

6300 Zug

Switzerland

(Address of principal executive offices and Zip Code)

41 415108022

(Registrant’s Telephone Number, Including Area Code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

Securities registered pursuant to Section 12(b) of the Act:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On August 30, 2023, the Board of Directors (the “Board”) of MoonLake Immunotherapeutics (the “Company”), upon recommendation by the Compensation Committee of the Board (the “Compensation Committee”), approved compensation increases for Jorge Santos da Silva, Ph.D., the Company’s Chief Executive Officer, Kristian Reich, Ph.D., the Company’s Chief Scientific Officer, and Matthias Bodenstedt, the Company’s Chief Financial Officer, reflecting the Company’s release of positive results from its Phase 2 MIRA trial and the Board’s desire to more closely align their compensation with similarly situated executives at peer companies. These changes include increasing (1) annual base salaries for Dr. Santos da Silva from CHF 450,000 to CHF 600,000, Dr. Reich from CHF 450,000 to CHF 600,000 and Mr. Bodenstedt from CHF 325,000 to CHF 475,000, each effective as of July 1, 2023; and (2) annual target bonuses (expressed as a percentage of base salary and subject to actual performance) for Dr. Santos da Silva from 50% to 55%, Dr. Reich from 50% to 55% and Mr. Bodenstedt from 40% to 50%.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

2